IDXX — IDEXX Laboratories Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for IDEXX Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,707	3,215	3,367	3,661	3,898
Cost of Revenue
Gross Profit	1,571	1,889	2,004	2,190	2,379
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	2,012	2,283	2,469	2,564	2,769
Operating Profit	695	932	899	1,097	1,128
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	662	903	860	1,061	1,110
Provision for Income Taxes
Net Income After Taxes	582	745	679	845	888
Minority Interest
Net Income Before Extraordinary Items
Net Income	582	745	679	845	888
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	582	745	679	845	888
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	6.73	8.65	8.03	10.1	10.7